How Vireo Growth Became the Story of 2026 Cannabis

Six months ago, you could say that Vireo Growth was a regional operator with a few state licenses and a quiet balance sheet. Today it is the seventh-largest US MSO by revenue, with operating footprints in California, Colorado, Florida, Minnesota, Missouri, Nevada, New Mexico, and Utah, and it got there through one of the most aggressive consolidation runs the industry has ever seen.

Between January and late April 2026, Vireo closed or announced six separate acquisitions - Schwazze's Colorado and New Mexico assets, Hawthorne Gardening, Eaze, PharmaCann's Colorado retail, FLUENT in Florida, and the still-pending Flowery transaction. The disclosed value of those deals exceeds $350M.

The Playbook

Credit bids on distressed paper. When Schwazze's senior secured notes traded down, Vireo bought them. Then it converted the notes directly into ownership of 45 dispensaries and two manufacturing facilities - a roughly $111M deal closed in March without writing a check for the equity. That structure is repeatable, and there is more distressed cannabis paper trading at discounts than there are buyers willing to take operating risk.

All-stock consideration with disciplined dilution. The Eaze deal (about $47M), the FLUENT deal (about $30M), and the PharmaCann Colorado deal (about $49M) are all stock transactions. None of them required Vireo to deplete cash reserves.

Strategic asset plays, not roll-ups. The Hawthorne acquisition - closed in April, valued at roughly $120M - is the most interesting move on the board. Hawthorne is the cannabis-cultivation arm of Scotts Miracle-Gro. Vireo issued shares and warrants and received approximately $110M in cash and net working capital in return. That transaction strengthened Vireo's balance sheet rather than weakening it.

Why This Is Bullish for the Industry

Cannabis M&A volume has been flat for two years. The 2026 surge - concentrated in Vireo but extending well beyond it - signals something new: capital is finding its way back into the industry, and the operators putting it to work are using structures that would not have been possible in 2022.

The largest disclosed deal of the year so far is Millstreet Credit Fund's $130M cash acquisition of Cannabist's Virginia operations, which closed in February. Five retail locations and 82,000 sq ft of cultivation in Richmond, paid in real money to a real seller. Cannabist had a prior agreement with Curaleaf and walked away to take Millstreet's higher offer. That kind of competitive bidding tension was almost absent in 2024 and 2025.

Below the headline, the deal pipeline has been steadily active. TerrAscend took a 35% stake in New Jersey's Union Chill for $13M. Planet 13 picked up a Strip-adjacent Las Vegas dispensary for $6.9M. Cannabist's Florida exit totaled $16.4M, including a MINT Cannabis and Shango purchase of Cannabist's Florida retail and cultivation portfolio. SNDL committed $32.2M in cash to acquire 32 retail stores from 1CM in a phased close. On the brand side, Wyld's pending acquisition of Grön creates an edibles platform with combined revenue around $440M - roughly twice the next-largest competitor.

Forbes summarized the 2026 environment with a useful line: "Cannabis M&A didn't vanish, it's just not happening in public." Viridian's deal tracker confirms the read - total cannabis M&A value through late 2025 hit roughly $2.10B across 49 transactions, up from $1.17B the year before, with fewer total deals and meaningfully larger average deal sizes.

What to Watch in H2 2026

First, the Flowery transaction. Vireo's binding MOU for the Florida operator has been pending for months and remains the largest unclosed deal on Vireo's docket. A close would extend Vireo's Florida footprint past 80 stores and accelerate its position ahead of any adult-use vote.

Second, rescheduling timing. Multiple buyers are already pricing rescheduling tailwinds into multiples. If the DOJ finalizes the Schedule III move in the first half of 2026, expect a second wave of M&A from acquirers sitting on capital waiting for that signal.

Third, the next credit bid. Schwazze will not be the last cannabis operator to default on senior secured notes. Whichever well-capitalized strategic acquirer is willing to underwrite the operating risk on the next one will likely pick up assets at multiples that make Vireo's 2026 run look conservative.

For an industry that spent two years being told it was in retreat, the deal flow tells a different story. The capital is here. The structures work. And the operators willing to move are building real scale on real terms.